Patent 7465738 was granted and assigned to Vertex Pharmaceuticals on December, 2008 by the United States Patent and Trademark Office.
The present invention relates to compounds useful as promoters of the SMN2 gene. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of Spinal Muscular Atrophy.